WO2021066136A1 - Agent thérapeutique pour dystrophies musculaires - Google Patents

Agent thérapeutique pour dystrophies musculaires Download PDF

Info

Publication number
WO2021066136A1
WO2021066136A1 PCT/JP2020/037520 JP2020037520W WO2021066136A1 WO 2021066136 A1 WO2021066136 A1 WO 2021066136A1 JP 2020037520 W JP2020037520 W JP 2020037520W WO 2021066136 A1 WO2021066136 A1 WO 2021066136A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
receptor antagonist
alkyl
crth2 receptor
combination
Prior art date
Application number
PCT/JP2020/037520
Other languages
English (en)
Japanese (ja)
Inventor
裏出　良博
Original Assignee
国立大学法人東京大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人東京大学 filed Critical 国立大学法人東京大学
Priority to JP2021551476A priority Critical patent/JPWO2021066136A1/ja
Publication of WO2021066136A1 publication Critical patent/WO2021066136A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a new therapeutic agent for muscular dystrophy.
  • Muscular dystrophy is a general term for muscle diseases in which muscle atrophy and weakness gradually progress while repeating destruction / degeneration (muscle necrotizing) and regeneration of muscle fibers.
  • Duchenne muscular dystrophy (Duchene MD: DMD) develops due to a dystrophin protein deficiency due to a mutation in the dystrophin gene on the short arm of the X sex chromosome (Xp21). It is the most common type of muscular dystrophy and affects 1 in 3,500 boys of all races.
  • the progression of muscular atrophy is the fastest, and muscular atrophy progresses rapidly from around 4 years old, requiring a wheelchair around 10 years old, wearing a respirator around 20 years old, and dying from heart failure etc. around 40 years old. ..
  • the diagnostic method for DMD has been established, but there is no cure. Only coping therapy is performed, such as rehabilitation to delay muscular atrophy, use of wheelchairs that complement motor function, wearing a respirator, and ensuring communication by using a personal computer after loss of motor function. Large amounts of medical expenses are spent on the lifelong care of patients.
  • Non-Patent Document 1 a drug for exon skipping that skips DMD mutant exons has been developed for three exons and clinical trials are being conducted. These drugs are specific to mutant exons, targeting about 10% of patients, and cannot treat patients with different mutant exons. In addition, there is a risk of developing autoantibodies to newly expressed dystrophin in the patient's body.
  • hematopoietic PGD 2 synthase hematopoietic PDG 2 synthase, HPGDS
  • DMD or the muscles polymyositis disease is known to be induced
  • Non-Patent Document 3 the urinary metabolic concentration of PGD 2 increases as the medical condition of DMD patients progresses.
  • Non-Patent Document 4 administration of the HPGDS inhibitor HQL79 reduces the collective necrotic degeneration region of mdx mice (Non-Patent Document 4), and that the HPGDS inhibitors TFC007, TAS204, and TAS205 show a myonecrotic inhibitory effect on DMD model animals. (Non-Patent Documents 5 and 6). A clinical trial of TAS205 in DMD patients has also been conducted (Non-Patent Document 7).
  • an object of the present invention is to provide a new therapeutic agent for MD that exerts an excellent effect on a wide range of patients, not a drug for exon skipping.
  • the present inventor investigated to develop an MD therapeutic agent having a stronger MD therapeutic effect, and found that the prostaglandin synthesis inhibitor and the CRTH2 receptor antagonist were used in combination to synergize these agents.
  • the present invention has been completed by finding that a myonecrosis inhibitory effect in DMD, which is more than 10 times stronger than those of these drugs, can be obtained.
  • An MD therapeutic agent comprising a combination of a prostaglandin synthesis inhibitor and a CRTH2 receptor antagonist.
  • An MD treatment method characterized by using a prostaglandin synthesis inhibitor and a CRTH2 receptor antagonist in combination.
  • the MD therapeutic agent of the present invention When the MD therapeutic agent of the present invention is used, a strong muscle necrotizing inhibitory effect more than 10 times that of both the prostaglandin synthesis inhibitor and the CRTH2 receptor antagonist can be obtained, and the progression of muscle weakness in MD patients is significantly reduced. Will be done. Therefore, by using the MD therapeutic agent of the present invention, the rate of muscle atrophy of MD patients can be greatly reduced, the period of wheelchair use and mechanical ventilation can be greatly extended, and the patient's self-sustaining period can be significantly extended. it can.
  • the combined use of the HPGDS inhibitor (TFC007) and the CRTH2 receptor antagonist (CAY10471) exhibits an inhibitory effect on myonecrotizing fasciitis.
  • the combined use of an HPGDS inhibitor (HQL79) and a CRTH2 receptor antagonist (OC000459) exhibits an inhibitory effect on muscle necrotizing.
  • the combined use of an HPGDS inhibitor (HQL79) and a CRTH2 receptor antagonist (OC000459) exhibits an inhibitory effect on muscle necrotizing.
  • the combined use of a non-steroidal anti-inflammatory drug (indomethacin) and a CRTH2 receptor antagonist (OC000459 or Cay10471) exhibits an inhibitory effect on myonecrosis.
  • the combined use of a non-steroidal anti-inflammatory drug (aspirin) and a CRTH2 receptor antagonist (OC000459, Cay10471 or BAYu3405) exhibits an inhibitory effect on myonecrosis.
  • the therapeutic agent for muscular dystrophy of the present invention contains a combination of a prostaglandin synthesis inhibitor and a CRTH2 receptor antagonist as an active ingredient.
  • prostaglandin synthesis inhibitors include cyclooxygenase inhibitors and prostaglandin D 2 (PGD 2 ) synthase inhibitors.
  • cyclooxygenase inhibitor non-steroidal anti-inflammatory drugs (NSAIDs) are preferable.
  • Non-steroidal anti-inflammatory agents include aspirin, mephenamic acid, diclofenac, fervinac, bromfenac, indomethacin, proglumetacin, acemetacin, bendazac, sulindac, etdrac, nevafenac, pyroxicum, lornoxicum, meloxicam, ibuprofen, naproxen.
  • Examples include biprofen, loxoprofen, planoprphen, zartprofen, selecoxib, salts thereof, esters thereof and the like. Of these, aspirin, diclofenac, indomethacin, ibuprofen, naproxen, ketoprofen, loxoprofen, salts thereof, and esters thereof are more preferable.
  • HPGDS is involved in DMD (Non-Patent Document 2), so the HPGDS inhibitor is more preferable as the PGD 2 synthase inhibitor used in the present invention.
  • HPGDS inhibitor include the following compounds.
  • a benzimidazole compound represented by the following general formula (1) or a salt thereof (Patent No. 4986853).
  • X 10 represents an oxygen atom or a carbonyl group
  • R 1 represents a furan ring having 1 to 3 substituents or a pyrrole ring which may have 1 to 3 substituents.
  • the compound represented by the general formula (1) in which the substituent is a phosphoric acid group or a phosphoric acid ester group is excluded.
  • R 11 represents an alkyl group having 1 to 6 carbon atoms
  • R 12 is a hydroxyl group, an alkyl group having 1 to 6 carbon atoms which may have a substituent
  • -(C O) -N (R 13).
  • R 13 and R 14 are the same or different, and may have a hydrogen atom or a substituent.
  • R 13 and R 14 may form a saturated heterocyclic group together with the nitrogen atom to which they are attached, indicating the number 1 to 6 alkyl group
  • R 15 has a hydrogen atom or a substituent.
  • It represents an alkyl group having 1 to 6 carbon atoms which may be present, and n represents 1 or 2.
  • X represents a CH or N atom
  • R 21 represents an alkyl group having 1 to 6 carbon atoms
  • R 23 , R 24 are the same or different, indicating a hydrogen atom, or an alkyl group having 1 to 6 carbon atoms which may have a substituent, or R 23 and R 24 together with the nitrogen atom to which they are attached. May form a saturated heterocyclic group
  • R 25 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or an aralkyl group which may have a substituent.
  • X 1 , X 2 , X 3 are the same or different, indicating N or CR 31 , m indicates 0 or 1
  • A is a phenylene group, a divalent saturated heterocyclic group, or Shows a divalent unsaturated heterocyclic group
  • B has a hydrogen atom, a halogen atom, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, a phenyl group which may have a substituent, and a substituent.
  • R 31 represents a hydrogen atom, a halogen atom, or an alkyl group.
  • R 32 and R 33 are the same or different, and represent a hydrogen atom, a phenyl group, an alkylcarbonyl group, a (saturated or unsaturated heterocyclic) carbonyl group, a phenylaminocarbonyl group, and an alkoxycarbonyl group.
  • R 34 represents a substituted alkyl group, a cycloalkyl group, a trifluoromethyl group, a phenyl group, an unsaturated heterocyclic group, a heteroaralkyl group, a saturated heterocyclic group, and an NR 36 R 37 group.
  • R 35 represents a phenyl group, an aralkyl group, an unsaturated heterocyclic group
  • R 36 and R 37 represent the same or different hydrogen atom, alkyl group, cyclohexyl group, phenyl group which may have a substituent, unsaturated heterocyclic group, aralkyl group, heteroaralkyl group?
  • R 36 and R 37 together with the nitrogen atom to which they are attached represent a pyrrolidyl or piperidyl group.
  • R 41 represents a 5- or 6-membered nitrogen-containing unsaturated heterocyclic group which may have a substituent, or a phenyl group which may have a substituent.
  • R 42 represents an unsaturated heterocyclic group or a phenyl group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms in the ring structure.
  • the unsaturated heterocyclic group represented by R 42 has 0 to 2 R 43- (CH 2 ) m- groups.
  • the phenyl group represented by R 42 has an R 43- (CH 2 ) m -group at either or both of its 3-position and 4-position.
  • R 47 or -SR 48 , R 44 and R 45 each have a hydrogen atom, an alkyl group having 1 to 6 carbon atoms which may have a substituent, an alkoxy group having 1 to 6 carbon atoms, and a substituent, respectively. Indicates an amino group which may be present, a saturated or unsaturated heterocyclic group which may have a substituent, an aryl group which may have a substituent and has 6 to 14 carbon atoms, or a carbonyl group which has a substituent.
  • R 44 and R 45 together with adjacent nitrogen atoms, are one or two selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms in addition to the adjacent nitrogen atoms in the ring structure, respectively. It may form a saturated or unsaturated cyclic amino group which may have a number of complex atoms, and the cyclic amino group may have a substituent.
  • R 46 represents an alkoxy group having 1 to 6 carbon atoms or ⁇ NR 49 R 50 groups which may have a hydrogen atom, a hydroxyl group and a substituent.
  • R 47 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms which may have a substituent, an alkenyl group having 2 to 6 carbon atoms which may have a substituent, or a carbonyl group having a substituent.
  • R 48 represents an alkyl group having 1 to 6 carbon atoms which may have a hydrogen atom or a substituent.
  • R 49 and R 50 are the same or different from each other, and have a hydrogen atom, an alkyl group having 1 to 6 carbon atoms which may have a substituent, and 1 to 6 carbon atoms which may have a substituent, respectively.
  • Indicates an amino group that may have an alkoxy group or a substituent, or R 49 and R 50 , together with adjacent nitrogen atoms, are one or two selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms in addition to the adjacent nitrogen atoms in the ring structure, respectively. It may form a saturated or unsaturated cyclic amino group which may have a number of complex atoms, and the cyclic amino group may have a substituent. ]
  • the compound represented by the following formula is more preferable.
  • R 51 is aryl, heteroaryl or C 5 -C 6 cycloalkyl group (these groups may have a substituent group);
  • the R 52 represents a hydrogen atom or a C 1 -C 4 alkyl group;
  • L 1 represents a direct bond or C 1 -C 6 alkylene group]
  • the compound or a salt thereof contains a solvate such as a hydrate.
  • the salt of the compound include pharmaceutically acceptable salts, for example, salts with alkali metals (lithium, sodium, potassium, etc.), alkaline earth metals (magnesium, calcium, etc.), ammonium, organic bases, and amino acids.
  • salts with inorganic acids hydroochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, etc.
  • organic acids acetic acid, citric acid, maleic acid, fumaric acid, benzenesulfonic acid, paratoluenesulfonic acid, etc.
  • These salts can be formed by conventional methods.
  • the CRTH2 receptor antagonist is a chemoattractant receptor-homologous molecule on Th2 cells (CRTH2) antagonist that is a PGD 2 receptor, and is attracting attention as an antiallergic agent such as a therapeutic agent for bronchial asthma.
  • CRTH2 receptor antagonist the following compounds are preferable.
  • R 61 indicates a hydrogen atom or a halogen atom
  • R 71 represents hydrogen, halogen, phenyl, halogenofenonyl, nitro group
  • R 72 represents a hydrogen atom or a C 1 -C 4 alkyl group
  • R 73 represents a hydrogen atom or a C 1 -C 4 alkyl group
  • R 74 represents a hydrogen atom or a C 1 -C 4 alkyl group
  • R 75 represents a hydrogen atom, halogen, alkyl, halogenoalkyl, alkoxy, phenoxy group
  • R 76 , R 77 , R 78 , R 79 indicate hydrogen atom, halogen atom, alkyl, halogenoalkyl group
  • X, Y indicate C or N
  • A indicates a carboxy group or a tetrazolyl group
  • L 1 is or a C 1 -C 3 represents alkylene or C 2 -C 3 alkenylene group; L 3 represents a direct bond, C 1 -C 3 alkylene or C 2 -C 3 alkenylene group; R a and R b are hydrogen atom, halogen, cyano, nitro, alkyl, halogenoalkyl , alkoxyhalogenoalkoxy, alkyl SO 2- , NH 2 SO 2- , alkyl NHSO 2- , di (alkyl) NSO 2- , aryl. , Aryloxy, shows arylalkoxy groups]
  • R 81 represents hydrogen, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, halogen, trifluoromethoxy or trifluoromethyl
  • R 82 is hydrogen, (C 1 -C 4) alkyl, (C 1 -C 2) alkoxy - (C 2 -C 3) alkyl, (C 1 -C 4) fluoroalkyl, or (C 3 -C 6) It represents (C 1 -C 2) alkyl group - cycloalkyl
  • R 83 represents a heteroaryl group substituted by or is 1, 2 or 3 substituents unsubstituted, the substituents are halogen, (C 1 -C 4) alkyl, (C 3 -C 6) cycloalkyl, (C 1 -C 4) alkoxy, are independently selected from the group consisting of (C 1 -C 4) fluoroalkyl and phenyl.
  • R c , R e , and R f are hydrogen, R d is halo, R g and R h are each independently substituted with hydrogen, or one or more halo substituents or one or more C 3- C 7 cycloalkyl groups, or C 1- C 6 alkyl or they are attached.
  • R g and R h are each independently substituted with hydrogen, or one or more halo substituents or one or more C 3- C 7 cycloalkyl groups, or C 1- C 6 alkyl or they are attached.
  • Ri is a C 1- C 6 alkyl optionally substituted with hydrogen or one or more halo substituents or one or more C 3- C 7 cycloalkyl groups.
  • R j is a phenyl, naphthalenyl, thiazole, biphenyl, quinolinyl or quinoxalinyl group and may be substituted with one or more halos, one or more halo substituents or one or more C 3- C 7 cycloalkyl groups.
  • Each R l is a C 1- C 6 alkyl that may be independently substituted with hydrogen or one or more halo substituents or one or more cycloalkyl groups.
  • R j is not an unsubstituted phenyl
  • R k is hydrogen or a C 1- C 6 alkyl optionally substituted with one or more halo substituents or one or more C 3- C 7 cycloalkyl groups.
  • R 4 , R 5 , R 6 and R 7 are independently substituted with hydrogen, halogen, haloalkyl, carboxy, alkyloxycarbonyl, respectively.
  • R 11 is hydrogen, alkyl, optionally substituted.
  • R 1 is carboxy, alkyloxycarbonyl, optionally substituted aminocarbonyl or tetrazolyl;
  • R 2 is hydrogen, alkyl or halogen;
  • R 15 is hydrogen or alkyl;
  • r is an integer of 0 to 2;
  • x is an integer of 0 to 3;
  • m is an integer of 1 to 3; dashed lines indicate the presence or absence of a bond;
  • E may be substituted aryl, optionally substituted A group represented by a good heteroaryl, alkyl, optionally substituted aralkyl or optionally substituted arylalkenyl),
  • x is an integer from 0 to 3;
  • m is an integer from 1 to 3; dashed lines represent the presence or absence of bonds;
  • E is optionally substituted aryl, optionally substituted heteroaryl, alkyl, substituted A group represented by an aralky
  • R 20 is hydrogen or alkyl
  • R 21 is a group represented by hydrogen or halogen.
  • R 13 is a group represented by hydrogen, alkyl, aralkyl, acyl or the formula: ⁇ OR 16 (where R 16 is hydrogen or alkyl), and R 14 is hydrogen or alkyl.
  • X indicates -SO 2 -or -SO 2 NR 3- ;
  • R 1 indicates hydrogen, F, Cl, CN or CF 3 ;
  • R 2 indicates hydrogen, F, Cl;
  • R 3 indicates hydrogen, C 1-6 alkyl or C 3-7 cycloalkyl;
  • Ar 1 represents a phenyl or 5- or 6-membered heteroaryl group (hydrogen, halogen, CN, alkyl, cycloalkyl, alkoxy may be substituted);
  • a 2 indicates a 5- or 6-membered heteroaryl group (hydrogen, halogen, CN, alkyl, cycloalkyl, alkoxy may be substituted)]
  • Ar 1 is preferably phenyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isooxazolyl, isothiazolyl, pyridinyl, pyridadinyl, pyrimidinyl, pyrazinyl, and Ar 2 is pyrrolyl, furanyl, thienyl, oxazolyl, Thiazolyl, imidazolyl, pyrazolyl, isooxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl are preferred.
  • CRTH2 receptor antagonist examples include the following compounds.
  • the compound or a salt thereof contains a solvate such as a hydrate.
  • the salt of the compound include pharmaceutically acceptable salts, for example, salts with alkali metals (lithium, sodium, potassium, etc.), alkaline earth metals (magnesium, calcium, etc.), ammonium, organic bases, and amino acids.
  • salts with inorganic acids hydroochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, etc.
  • organic acids acetic acid, citric acid, maleic acid, fumaric acid, benzenesulfonic acid, paratoluenesulfonic acid, etc.
  • These salts can be formed by conventional methods.
  • these drugs were used alone when a prostaglandin synthesis inhibitor and a CRTH2 receptor antagonist were used in combination, especially when an HPGDS inhibitor and a CRTH2 receptor antagonist were used in combination. It dramatically suppresses muscle necrotizing in muscular dystrophy compared to the case. That is, these drugs synergistically suppress muscle necrotizing in muscular dystrophy by their combination, and are useful as a therapeutic agent for muscular dystrophy, particularly as a therapeutic agent for DMD.
  • mdx mice muscular dystrophy model mice
  • a phenomenon common to DMD patients such as elevation of serum creatine kinase and pyruvate kinase, which are markers of muscle necrosis, occurs.
  • Pathological findings are similar to those of DMD patients.
  • a prostaglandin synthesis inhibitor and a CRTH2 receptor antagonist are administered in combination to these mdx mice, in particular, when an HPGDS inhibitor and a CRTH2 receptor antagonist are administered in combination, these agents are administered alone.
  • the increase in serum creatine kinase was remarkably suppressed as compared with the case of administration.
  • T3-induced myocardial injury in this mdx model mouse can also be synergistically suppressed by the combined use of a prostaglandin synthesis inhibitor and a CRTH2 receptor antagonist. Therefore, by using the MD therapeutic agent of the present invention, the rate of muscle atrophy of MD patients can be greatly reduced, the period of wheelchair use and mechanical ventilation can be greatly extended, and the patient's self-sustaining period can be significantly extended. it can.
  • the drug of the present invention may be a combination of a prostaglandin synthesis inhibitor and a CRTH2 receptor antagonist, and two compositions containing each drug may be used in combination (combination drug). It may be a pharmaceutical composition containing.
  • the concomitant drug or pharmaceutical composition of the present invention can be administered in any administration form, and the preparation can be selected according to the administration form. Examples of the orally administered preparation include tablets, capsules, granules, powders, syrups and the like. Examples of parenteral preparations include injections, suppositories, inhalants, transdermal absorbents, external preparations for skin, eye drops, nasal drops and the like. When an injection is selected, the route of administration includes subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal injection and intravenous injection.
  • an oral liquid preparation When preparing an oral liquid preparation, an oral liquid preparation, a syrup preparation, an elixir preparation, etc. can be produced by adding a flavoring agent, a buffering agent, a stabilizer, a preservative, etc. by a conventional method.
  • a pH adjuster, a stabilizer, an isotonic agent can be added, and a subcutaneous, muscular, or intravenous injection can be produced by a conventional method.
  • a preparation (composition) containing a prostaglandin synthesis inhibitor and a preparation (composition) containing a CRTH2 receptor antagonist are used in combination.
  • they may be kit drugs in which the separately formulated drugs are combined with the instructions describing the respective administration methods.
  • the dosage forms of the respective formulations may be the same or different, and the dosing intervals may be the same or different.
  • one dosage form for example, a tablet contains these two drugs. preferable.
  • the dose of the medicament of the present invention varies depending on the compound used, the age, body weight, symptoms, etc. of the patient, but the daily dose of the prostaglandin synthesis inhibitor is preferably 0.01 to 10 mg / kg. More preferably, 05 to 10 mg / kg.
  • the daily dose of the CRTH2 receptor antagonist is preferably 0.01 to 10 mg / kg, more preferably 0.05 to 5 mg / kg.
  • Example 1 (Method) Solvent (5% DMSO in 5% methylcellulose-containing saline), HPGDS inhibitor TFC007 (30 mg / kg), CRTH2 receptor antagonist CAY10471 (1.0 mg / kg), or a combination of two agents (TFC007, 3 mg / kg + CAY10471, 0.1 mg / kg) was subcutaneously administered daily to muscular dystrophy model mice (mdx mice (C57BL / 6)) for 4 to 4 weeks after birth to measure serum creatine kinase activity (marker of skeletal muscle necrosis). .. (result) The results are shown in FIG. From FIG.
  • Example 2 (Method) Solvent (5% DMSO in 5% methylcellulose-containing saline), HPGDS inhibitor HQL79 (30 mg / kg), CRTH2 receptor antagonist OC000459 (1.0 mg / kg), or a combination of two agents (HQL79, 3 mg / kg + OC000459, Serum creatine after subcutaneous administration of 0.1 mg / kg) to muscular dystrophy model mice (mdx mice (C57BL / 10)) every 2-3 days (weekly, Monday, Wednesday, Friday) for 4 to 2 weeks after birth. Kinase activity (marker of skeletal muscular necrosis) was measured. (result) The results are shown in FIG. From FIG. 2, when the HPGDS inhibitor and the CRTH2 receptor antagonist are used in combination, the doses thereof are 1/10 of those of the single dose, but stronger than those of the single dose. It showed a creatine kinase activity lowering effect.
  • Example 3 (Method) Solvent (5% DMSO in 5% methylcellulose-containing saline), HPGDS inhibitor HQL79 (30 mg / kg), CRTH2 receptor antagonist OC000459 (0.5 mg / kg), or a combination of two agents (HQL79, 3 mg / kg) (Kg + OC000459, 0.1 mg / kg) was subcutaneously administered to muscular dystrophy model mice (C57BL / 10-mdx mice) every 2-3 days (weekly, Monday, Wednesday, Friday) for 4 to 4 weeks after birth. Later serum creatinine kinase activity (marker of skeletal muscular necrosis) was measured. (result) The results are shown in FIG. From FIG.
  • Example 4 (Method) Solvent (5% DMSO in 5% methylcellulose-containing physiological saline), prostaglandin synthesis inhibitor indomethacin (1 mg / kg), or a combination of prostaglandin synthesis inhibitor indomethacin and CRTH2 receptor antagonist (indomethacin, 0. 1 mg / kg + OC000459, 0.1 mg / kg or indomethacin, 0.1 mg / kg + Cay10471, 0.1 mg / kg) was subcutaneously administered to muscle dystrophy model mice (C57BL / 10-mdx mice) daily from 16 weeks to 10 days after birth. Later serum creatinine kinase activity (marker of skeletal muscle necrosis) was measured.
  • Example 5 (Method) Solvent (5% DMSO in 5% methylcellulose-containing physiological saline), prostaglandin synthesis inhibitor aspirin (150 mg / kg), or a combination of prostaglandin synthesis inhibitor aspirin and CRTH2 receptor antagonist (aspirin, 150 mg / kg) kg + Cay10471, 0.1 mg / kg; aspirin, 150 mg / kg + OC000459, 0.1 mg / kg; or aspirin, 150 mg / kg + BAYu3405, 10 mg / kg) in muscle dystrophy model mice (C57BL / 6-mdx mice), 4 weeks old Serum creatinine kinase activity (marker of skeletal muscle necrosis) was measured after subcutaneous administration every day for 4 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouvel agent thérapeutique pour dystrophies musculaires qui n'est pas un médicament de saut d'exon et qui exerce un excellent effet sur des patients sur une grande portée.　L'agent thérapeutique pour dystrophies musculaires comprend une combinaison d'un inhibiteur de la synthèse des prostaglandines avec un antagoniste du récepteur CRTH2.
PCT/JP2020/037520 2019-10-03 2020-10-02 Agent thérapeutique pour dystrophies musculaires WO2021066136A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021551476A JPWO2021066136A1 (fr) 2019-10-03 2020-10-02

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-182859 2019-10-03
JP2019182859 2019-10-03

Publications (1)

Publication Number Publication Date
WO2021066136A1 true WO2021066136A1 (fr) 2021-04-08

Family

ID=75338144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/037520 WO2021066136A1 (fr) 2019-10-03 2020-10-02 Agent thérapeutique pour dystrophies musculaires

Country Status (2)

Country Link
JP (1) JPWO2021066136A1 (fr)
WO (1) WO2021066136A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005119984A (ja) * 2003-10-14 2005-05-12 Osaka Bioscience Institute 筋変性疾患の治療用医薬組成物およびそのスクリーニング方法
US20090088400A1 (en) * 2007-09-11 2009-04-02 Puymirat Jack Prostaglandin e2 modulation and uses thereof
WO2017104728A1 (fr) * 2015-12-16 2017-06-22 国立大学法人東京大学 Médicament destiné à traiter une allergie alimentaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005119984A (ja) * 2003-10-14 2005-05-12 Osaka Bioscience Institute 筋変性疾患の治療用医薬組成物およびそのスクリーニング方法
US20090088400A1 (en) * 2007-09-11 2009-04-02 Puymirat Jack Prostaglandin e2 modulation and uses thereof
WO2017104728A1 (fr) * 2015-12-16 2017-06-22 国立大学法人東京大学 Médicament destiné à traiter une allergie alimentaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BULIEN, DITTA ET AL.: "The effect of indomethacin on serum and skeletal muscle enzyme activities of dystrophic hamsters", BIOCHEMICAL PHARMACOLOGY, vol. 25, no. Issue 8, 15 April 1976 (1976-04-15), pages 981 - 983, XP025510138, DOI: 10.1016/0006-2952(76)90327-0 *
MOHRI, IKUKO: "Inhibition of prostaglandin D synthase suppresses muscular necrosis", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 174, no. 5, May 2009 (2009-05-01), pages 1735 - 1744, XP008166859, DOI: 10.2353/ajpath.2009.080709 *

Also Published As

Publication number Publication date
JPWO2021066136A1 (fr) 2021-04-08

Similar Documents

Publication Publication Date Title
US20220339169A1 (en) Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
EP2911664B1 (fr) Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
US20100076037A1 (en) Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CN112638866B (zh) 索拉非尼衍生物的共晶体及其制备方法
JP2019515884A5 (fr)
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
RU2010148762A (ru) Тетразольные соединения для снижения концентрации мочевой кислоты
US11613528B2 (en) Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
TW201912153A (zh) 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
EP2809314A1 (fr) Traitement de la douleur neuropathique avec des inhibiteurs de seh
JP2021530488A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
JP2018203774A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
WO2021066136A1 (fr) Agent thérapeutique pour dystrophies musculaires
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
US20020147206A1 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
US20100056460A1 (en) Combination of organic compounds
JP7535797B2 (ja) 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
CA3157656A1 (fr) Utilisation de nictotinamide mononucleotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoide et compositions correspondantes
US20080139573A1 (en) Treatment of resistant Schizophrenia and other CNS disorders
WO2024010030A1 (fr) Agent destiné à réduire le taux de myostatine dans le sang
TW201806601A (zh) σ受體配體在皰疹後遺疼痛中的用途
JP5559696B2 (ja) 糖尿病性腎症の治療剤
TW202425969A (zh) 吲唑吡啶酮化合物及其用途
JP2006096664A (ja) 肝繊維化抑制剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20872427

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021551476

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20872427

Country of ref document: EP

Kind code of ref document: A1